BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31895690)

  • 21. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
    PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.
    Amaral CL; Freitas LB; Tamura RE; Tavares MR; Pavan IC; Bajgelman MC; Simabuco FM
    BMC Cancer; 2016 Aug; 16():602. PubMed ID: 27491285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
    Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
    Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ
    Mol Cancer Ther; 2014 Jan; 13(1):190-201. PubMed ID: 24194567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer.
    Schnepp PM; Ahmed A; Escara-Wilke J; Dai J; Shelley G; Keller J; Mizokami A; Keller ET
    BMC Cancer; 2021 Dec; 21(1):1316. PubMed ID: 34879849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells.
    Forde JC; Perry AS; Brennan K; Martin LM; Lawler MP; Lynch TH; Hollywood D; Marignol L
    Urol Oncol; 2012; 30(6):912-9. PubMed ID: 21176881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
    Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen‑related receptor γ promotes the migration and metastasis of endometrial cancer cells by targeting S100A4.
    Hua T; Wang X; Chi S; Liu Y; Feng D; Zhao Y; Wang H
    Oncol Rep; 2018 Aug; 40(2):823-832. PubMed ID: 29901152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptome changes induced by docetaxel in human mammary cell lines expressing different levels of ERBB2.
    Dos Santos ML; Gimenes KP; Silva WA; Nagai MA
    Int J Mol Med; 2009 Jun; 23(6):733-43. PubMed ID: 19424599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
    Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
    World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway.
    Pan Y; Chen J; Tao L; Zhang K; Wang R; Chu X; Chen L
    Oncotarget; 2017 May; 8(20):33144-33158. PubMed ID: 28388536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
    Yano S; Matsuyama H; Hirata H; Inoue R; Matsumoto H; Ohmi C; Miura K; Shirai M; Iizuka N; Naito K
    Oncol Rep; 2006 Jun; 15(6):1453-60. PubMed ID: 16685379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
    O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R
    Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
    Feng Q; He P; Wang Y
    Gene; 2018 Jun; 658():152-158. PubMed ID: 29518547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.
    Qiu S; Deng L; Bao Y; Jin K; Tu X; Li J; Liao X; Liu Z; Yang L; Wei Q
    Anticancer Drugs; 2018 Oct; 29(9):871-879. PubMed ID: 29944470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
    Zhang K; Yu M; Hao F; Dong A; Chen D
    Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.